MedTrace Logo

GLU-xx Formulations in Individuals With Impaired Glucose Tolerance

NCT01468376 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2012-01-31

No results posted yet for this study

Summary

The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.

Conditions

  • Impaired Glucose Tolerance

Interventions

DIETARY_SUPPLEMENT

GLU-01

14 day dosing

DIETARY_SUPPLEMENT

GLU-02

14 day dosing

DIETARY_SUPPLEMENT

GLU-03

14 day dosing

DIETARY_SUPPLEMENT

GLU-04

14 day dosing

DIETARY_SUPPLEMENT

GLU-05

14 day dosing

DIETARY_SUPPLEMENT

GLU-06

14 day dosing

Sponsors & Collaborators

  • Afexa Life Sciences Inc

    lead INDUSTRY

Principal Investigators

  • Jay Udani, MD · Medicus Research LLC/Staywell Research LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468376 on ClinicalTrials.gov